Porzsolt Franz, Schreyögg Jonas
Klinische Okonomik, Universität Ulm, Ulm, Germany.
Med Klin (Munich). 2009 Aug;104(8):622-30. doi: 10.1007/s00063-009-1134-3. Epub 2009 Aug 23.
When depicting the relationship between evidence and the cost of an innovation in the health-care system, the overall risks of assessment, the redistribution of risks in a regulated market, and the ethical consequences must first be taken into account. There are also evidence-based criteria and economic considerations which are relevant when calculating the cost of an innovation. These topics can indicate, but not exhaustively deal with the complicated relationship between scientific evidence and calculating the cost of an innovation in the health-care system. The following three statements summarize the current considerations in the continuing discussion of this topic: *Scientific evidence undoubtedly exists which should be taken into consideration when calculating the cost of an innovation in the health-care system. *The existing scientific evidence is, however, not sufficient to reach such a decision. Additional information about the benefit perceived by the patient is required. *No standardized method exists to measure this additional information. Therefore, a definition problem also exists in the health-care system when setting a price according to scientific evidence.
在描述医疗保健系统中证据与创新成本之间的关系时,必须首先考虑评估的总体风险、监管市场中风险的重新分配以及伦理后果。在计算创新成本时,还有基于证据的标准和经济考量因素。这些主题可以表明,但无法详尽地处理科学证据与计算医疗保健系统中创新成本之间的复杂关系。以下三个陈述总结了在该主题持续讨论中的当前考量:“在计算医疗保健系统中创新成本时,无疑存在应予以考虑的科学证据。”“然而,现有的科学证据不足以做出这样的决定。还需要有关患者感知益处的更多信息。”“不存在衡量此额外信息的标准化方法。因此,在根据科学证据定价时,医疗保健系统中也存在定义问题。”